NCT Number: NCT02323568
Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.
This project is part of a large multicenter multidisciplinary program that will thoroughly explore the needs and difficulties of patients with BCR as well as those involved in their care. The results of this research program will propose recommendations for better structure and understand the follow up of these patients.
From the limited data in the literature, the long-term remission in patients with ovarian cancer reported a significant and persistent fatigue, poor QoL, disorders of sexuality as well as somatic and mental illness; consumption is also a medical records for these patients.
In this context, our team has initiated a large case-control study to assess fatigue (identified major problem in the long-term remission in patients with ovarian cancer), QoL and rehabilitation of patients in remission from an epithelial ovarian cancer (regardless of the stage of cancer at diagnosis, early or advanced) 3 years after the initial treatment, compared with women of the same age without ovarian cancer or serious chronic disease , from the general population.
Patients and controls complement standardized and validated self-administered questionnaire (part 1). This study investigated 215 patients in long remission from ovarian cancer compared to 215 women of the same age without cancer. Recruitment of patients is currently underway, in close collaboration with teams from the Group GINECO very involved in this project.
Following this step, an additional component is planned: it is to offer patients who participated in part 1, a specific gynecological consultation to assess in detail the effects of the treatments in order to better meet the needs of patients .dropoff window
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Not applicable
Primary location
CHU, Besançon, France
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age> 18 years;
- Patients who received optimal treatment (surgery, chemotherapy ...)
- Patients with epithelial ovarian cancer after first-line treatment;
- Patients without other cancer (except basal cell skin carcinoma and breast cancer in situ);
- Patients without clinical relapse, biological or radiological documented at least 3 years after the initial treatment (from the end date of first line chemotherapy);
- The interviews treatments are not recognized in the period;
- Patients may be included regardless of the stage of cancer at diagnosis (early or late)
- Patients who have signed their written consent to participate in the part 2 of the study Vivrovaire;
- Patients who participated in part 1 of Vivrovaire study.
Exclusion criteria
- Psychiatric pathology can disrupt the conduct of the study or to prevent the interpretation of results;
- Persons deprived of liberty;
- Major subject to a measure of legal protection or unable to consent.
Treatment and study plan
Primary outcomes
-
Physical sequelae measured by the functional and biological effects
Time frame: At inclusion
Sponsors and collaborators
Lead sponsor
Centre Francois Baclesse
Other
Collaborators
- Fondation de France
- Ligue contre le cancer, France
Registry information
Acronym: VIVROVAIRE 2
Important dates
- Study start
- 2014
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Dec 23, 2014
- Registry last updated
- Feb 10, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
NCT05483933
Adnexal Diseases, Carcinoma
Little Rock, Arkansas, United States
View Trial DetailsA Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT06087289
Adnexal Diseases, Carcinoma
Odense, Denmark
View Trial DetailsCATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
NCT04676334
Adnexal Diseases, Carcinoma
London, Ontario, Canada
View Trial DetailsStudy of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer
NCT02312661
Adnexal Diseases, Carcinoma
Groningen, Netherlands
View Trial Details